Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding increases in their interests in Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing details an increase in shareholdings for ten individuals following the re-investment of dividends paid on October 4, 2012. The shares were purchased at a price of 1,457.14 pence per share on October 8, 2012. Specific increases include:
- Dr M M Slaoui: 232,081 shares
- Mr S M Bicknell: 68,107 shares
- Mr R G Connor: 24,777 shares
- Mr M Dunoyer: 328,383 shares
- Mr S A Hussain: 736,891 shares
- Mr D S Redfern: 253,960 shares
- Ms C Thomas: 248,247 shares
- Mr P C Thomson: 98,343 shares
- Dr P J T Vallance: 223,919 shares
- Mr C Weber: 250,439 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares acquired by directors through dividend re-investment plans.
- Confirm the share price of 1,457.14 pence per share on October 8, 2012.
- Review the dividend payment date of October 4, 2012, to understand the timing of the re-investment.
- Check subsequent filings for any changes in director holdings or additional transactions.